KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Supernus Pharmaceuticals (SUPN) Change in Receivables (2016 - 2025)

Supernus Pharmaceuticals (SUPN) has disclosed Change in Receivables for 15 consecutive years, with $16.4 million as the latest value for Q4 2025.

  • Quarterly Change in Receivables rose 592.92% to $16.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $22.3 million through Dec 2025, up 1173.34% year-over-year, with the annual reading at $22.3 million for FY2025, 1173.34% up from the prior year.
  • Change in Receivables for Q4 2025 was $16.4 million at Supernus Pharmaceuticals, up from $7.1 million in the prior quarter.
  • The five-year high for Change in Receivables was $16.4 million in Q4 2025, with the low at -$22.0 million in Q1 2023.
  • Average Change in Receivables over 5 years is $698000.0, with a median of $2.9 million recorded in 2021.
  • The sharpest move saw Change in Receivables crashed 476.36% in 2023, then surged 592.92% in 2025.
  • Over 5 years, Change in Receivables stood at $3.5 million in 2021, then crashed by 59.6% to $1.4 million in 2022, then surged by 69.74% to $2.4 million in 2023, then plummeted by 239.37% to -$3.3 million in 2024, then soared by 592.92% to $16.4 million in 2025.
  • According to Business Quant data, Change in Receivables over the past three periods came in at $16.4 million, $7.1 million, and -$4.8 million for Q4 2025, Q3 2025, and Q2 2025 respectively.